Lazard Asset Management’s Kailera Therapeutics KLRA Stock Holding History
Bought
Maintained
Sold
Other funds holding KLRA
Lazard Asset Management's KLRA Position: Q3 2026 in Review
Lazard Asset Management increased its Kailera Therapeutics (KLRA) stake by 67% in Q3 2026, buying an estimated $544K and bringing the position to 80,580 shares worth $920K. The position accounts for ﹤0.01% of the portfolio, ranked #1219.
Lazard Asset Management first reported a position in KLRA in Q2 2026 and has held it in 2 quarters since. The position peaked at $1.07M in Q2 2026. 132 funds tracked by Wall St. Rank hold KLRA as of Q3 2026.
- Lazard Asset Management held 80,580 shares of Kailera Therapeutics worth $920K as of Q3 2026.
- Lazard Asset Management bought 32,189 Kailera Therapeutics shares in Q3 2026, an estimated $544K.
- Kailera Therapeutics made up ﹤0.01% of Lazard Asset Management's portfolio in Q3 2026, its #1219 holding.
- Lazard Asset Management first reported a position in Kailera Therapeutics in Q2 2026 and has held it in 2 quarters since.
- Lazard Asset Management's Kailera Therapeutics position peaked at $1.07M in Q2 2026.
- 132 funds tracked by Wall St. Rank held Kailera Therapeutics as of Q3 2026.
Based on Lazard Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.